Genocea Biosciences Inc (NASDAQ:GNCA) Investor Securities Class Action Lawsuit 11/01/2017

If you purchased a significant amount of shares of Genocea Biosciences Inc (NASDAQ:GNCA) between May 5, 2017 and September 25, 2017, and / or if you purchased any NASDAQ:GNCA shares prior to May 5, 2017 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: January 2, 2018. NASDAQ:GNCA investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Genocea Biosciences
Case Name: 
Genocea Biosciences Shareholder Class Action Lawsuit 11/01/2017
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: GNCA
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
11/01/2017
Class Period Begin: 
05/05/2017
Class Period End: 
09/25/2017
Court of Filing: 
U.S. District Court for the District of Massachusetts
Deadline To File for Lead: 
01/02/2018
Summary: 

An investor in shares of Genocea Biosciences Inc (NASDAQ:GNCA) filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Genocea Biosciences Inc in connection with certain allegedly false and misleading statements made between May 5, 2017 and September 25, 2017.

According to the complaint the plaintiff alleges on behalf of purchasers of Genocea Biosciences Inc (NASDAQ:GNCA) common shares between May 5, 2017 and September 25, 2017, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that between May 5, 2017 and September 25, 2017, the Defendants made false and/or misleading statements and/or failed to disclose that the Company's finances were insufficient to support Phase 3 trials of GEN-003, that accordingly, Genocea had overstated the prospects for GEN-003, and that as a result of the foregoing, Genocea's public statements were materially false and misleading at all relevant times.

Cambrdige, MA based Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. Genocea Biosciences Inc went public in February 2014 and shares of Genocea Biosciences Inc (NASDAQ:GNCA) reached $22.70 per share in June 2014.

On September 25, 2017, after the market closed, Genocea Biosciences Inc disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce.

Shares of Genocea Biosciences Inc (NASDAQ:GNCA) declined on November 1, 2017 to as low as $1.08 per share.